The Ozempic Wars: A Tale of Two Pharmaceutical Giants The pharmaceutical industry has long been a hotbed of competition and innovation, but the latest dispute between Novo Nordisk and Eli Lilly raises important questions about advertising in healthcare.
At its core, the issue revolves around allegations that Eli Lilly's advertisements for its weight loss and diabetes treatments are misleading and deceptive.
Novo Nordisk claims that Eli Lilly is using outdated studies to make comparisons between their products, Mounjaro and Zepbound, and Novo Nordisk's own Ozempic and Wegovy.